MDRNA granted Chinese patent for use of nucleic acids in cancer treatment

Links shared publicly online about this topic.

1,426
total visits

MDRNA granted Chinese patent for use of nucleic acids in cancer treatment

MDRNA, Inc., a leading RNAi-based drug discovery and development company, today announced that the State Intellectual Property Office of the People's Republic of China (PRC) has issued a Notification of Granting Patent Rights for PRC 200480018784 which includes the use of nucleic acids, e.g., an siRNA, for the treatment of cancer. The patent describes modulation of claudins, which are proteins implicated in tumor progression and metastasis.

View full resource at news-medical.net

Tags: Cancer, Protein, Drug, Oncology, News